Search This Blog

Saturday, August 3, 2019

Ecommerce Firm Rakuten Puts $100M in Rakuten Medical, Upping Stake to 22.5%

Rakuten Medical announced it had raised $100 million in a Series C-1 Preferred Stock financing. The financing came from Rakuten, an internet services company based in Tokyo. This raise increased Rakuten’s equity share of Rakuten Medical to 22.5%.
Rakuten Medical was formerly called Aspyrian Therapeutics. Since launching in 2015, it has raised almost $500 million. The name change took place earlier this year and was related to the extensive investment by Mickey Mikitani, the Japanese billionaire who founded and ran online retailer Rakuten. Mikitani plans to expand the strategic connections between Rakuten Medical and Rakuten. Mikitani is chairman and chief executive officer of Rakuten Medical.

“Culturally, the technology industry has revolutionized society by being bold, action-driven and innovative,” stated Mikitani. “And we hope to do the same at Rakuten Medical by exploring opportunities that will combine Rakuten’s technology expertise with Rakuten Medical’s first-in-class photoimmunotherapy platform.”
Rakuten Medical has offices in the U.S., Tokyo, Taiwan, Amsterdam and Sinn-Fleisbach, Germany. It is focused on precision-targeted therapies via its proprietary photoimmunotherapy platform.
The company’s lead program is ASP-1929, which was given Fast Track designation from both the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare. It is in Phase III clinical trials for recurrent head and neck squamous cell carcinoma (rHNSCC). The Phase II trial indicated the therapy had a high response rate in patients who failed existing treatment options.
The company’s technology is made up of a drug and device combination that uses monoclonal antibodies attached to a dye (IRDye 700DX). Using non-thermal red light, it excites the dye, which causes rapid and selective cell death and tumor necrosis with minimal effects to normal tissue. The monoclonal antibodies deliver the dye to the cancer cells.
The company plans to use the additional funds to expand development of the phototherapy program, bolster its business functions and to look for new investigational compounds and indications for its tech platform.
“The additional investment from Rakuten solidifies our commitment to accelerating Rakuten Medical’s business and commercial development,” Mikitani stated. “I believe we can cultivate a sustainable health care ecosystem to provide patients with safe and easy access to, and better care in, the treatment of cancer, regardless of their nationality or income.”

Rakuten was founded in Tokyo in 1997 as an online marketplace. It has expanded into e-commerce, fintech, digital content and communications. The Rakuten Group employs more than 17,000 people with operations in 30 countries.
On May 31, Rakuten Medical opened offices in Amsterdam, Netherlands and Taipei, Taiwan. The Amsterdam office will act as the company’s European headquarters. Its office in Germany, which opened in 2016, will focus on its development and manufacturing operations for PIT devices. The Taipei site will be a subsidiary of Rakuten Medical Japan and support growth and future commercial launches.
At the time, Mikitani stated, “Rakuten Medical is poised to become a fully integrated biotechnology company, and we are gearing up to build and commercialize a strong pipeline of anti-cancer therapies based on our proprietary photoimmunotherapy platform. Expanding our presence in Europe and Asia is critical for us to deliver upon our mission of conquering cancer and delivering safe and effective treatments that could transform and improve the lives of patients globally.”

Trump Administration Gets Smart On Pre-Existing Conditions

Last Thursday afternoon, the Trump administration released its final rule regarding Health Reimbursement Arrangements (HRAs). The 497-page document will take lawyers and employment professionals weeks to absorb and digest fully. But in a nutshell, the rule will help to make coverage more portable and affordable—while also going a long way to resolve the problem of pre-existing conditions.
As I first explained when the administration proposed this HRA rule back in October, much of the problem surrounding pre-existing conditions revolves around portability. Because most Americans don’t own their own health coverage—their employers do—when people lose their job, they lose their health coverage. The pre-existing condition problem emerges when people develop a costly medical condition while at one job, then have to switch jobs or otherwise leave their employer plan.
Solving the portability problem—allowing health coverage to go from job to job—would go a long way towards solving the pre-existing condition problem. Of course, Democrats don’t talk about solving the portability problem because they don’t wantto solve it. They want the government to control everything through a single-payer health care system. That’s why they spend so much time talking about a symptom (people with pre-existing conditions who can’t get coverage) rather than the underlying disease (coverage not being portable).
But if people owned their own insurance policies, they could change jobs easily, without fear of losing their coverage. Moreover, they would get to pick the kinds of benefit designs and doctor networks they want, rather than being stuck with what their employer picks for them.
The final rule accomplishes both objectives. It enhances portability by allowing employers to give their workers a (tax-free) contribution to an HRA, so employees can buy the plan that works best for them. If there’s any difference between the employer’s contribution and the total premium—for instance, an employer contributes $300 per month, and the worker selects a plan with a $350 monthly premium—the worker can pay the difference on a pre-tax basis, so long as he purchases the plan outside of the Obamacare exchanges. Best of all, because employees own the plans and not the employer, they can keep their coverage when they change jobs.
This change also improves affordability, in two key respects. First, individuals can buy just the coverage they want, rather than the coverage their employer gives them. Currently, if an employer plan offers particular benefits that an employee does not value, or a provider network a worker does not need, the worker can only buy an alternative plan by forfeiting their employer’s subsidy towards their health insurance—an unattractive and irrational option for most. The HRA option will allow workers to retain their employer’s subsidy, yet purchase more tailored coverage.
Second, more people purchasing coverage individually will create a more robust marketplace, increasing competition. Carriers may move into the market for individual coverage, and even create new options to attract additional business—both changes that will help consumers, and mitigate premium increases.
The final rule does include important safeguards to ensure that businesses don’t just try to “dump” their sickest employees onto individual insurance plans, raising premiums on the Obamacare exchanges. Most notably, if they elect the HRA option, firms must apply it to an entire class of workers—for instance, all full-time workers, or all workers in a certain geographic area. Moreover, employers cannot vary their contributions to workers’ HRAs, except by the employee’s age and number of dependents.
The rule could eventually lead to dramatic changes in Americans’ health-coverage options, but it includes provisions designed to phase those changes in over time. Under the rule, employers cannot offer traditional group health coverage to any class of workers that has access to an individual coverage HRA. In other words, employers can choose the “new” HRA model to deliver benefits to their workers, or the “old” (i.e., existing) model for their workers, but not both (at least not for the same class of workers).
However, the final rule also includes a critically important grandfathering provision, which will provide businesses the option for a smoother transition. Under this provision, an employer can apply the HRA model to new hires, while allowing existing employees to maintain their traditional group insurance. For instance, an employer could state that any worker joining the firm after the HRA rule takes effect (on January 1, 2020) would receive health coverage using the new rules, while current workers would remain on the firm’s existing employer plan.
The HRA rule represents the last element of President Trump’s October 2017 executive order on health care (the others being short-term insurance and Association Health Plans)—and potentially the most significant. The HRA coverage option presents a “win-win” for both employees and employers: Workers get portable insurance, and the chance to select their own plan, while businesses (particularly small businesses) that select this option can avoid the paperwork and bureaucracy that comes with running a health plan for their employees.
Conservatives concerned about pre-existing conditions should study this rule closely, and cite it every time the left mounts political attacks over the issue. Liberals want the government to control all of health care, as evidenced by their single-payer push. Conversely, conservatives want doctors and patients to make their own health-care decisions. Last week’s HRA rule will accomplish just that.

MIT AI predicts breast cancer up to 5 years early, for white, black patients

BreastCancerAI
MIT’s Computer Science and Artificial Intelligence Lab has developed a new deep learning-based AI prediction model that can anticipate the development of breast cancer up to five years in advance. Researchers working on the product also recognized that other similar projects have often had inherent bias because they were based overwhelmingly on white patient populations, and specifically designed their own model so that it is informed by “more equitable” data that ensures it’s “equally accurate for white and black women.”
That’s key, MIT notes in a blog post, because black women are more than 42 percent more likely than white women to die from breast cancer, and one contributing factor could be that they aren’t as well-served by current early detection techniques. MIT says that its work in developing this technique was aimed specifically at making the assessment of health risks of this nature more accurate for minorities, who are often not well represented in development of deep learning models. The issue of algorithmic bias is a focus of a lot of industry research and even newer products forthcoming from technology companies working on deploying AI in the field.
This MIT tool, which is trained on mammograms and patient outcomes (eventual development of cancer being the key one) from over 60,000 patients (with over 90,000 mammograms total) from the Massachusetts General Hospital, starts from the data and uses deep learning to identify patterns that would not be apparent or even observable by human clinicians. Because it’s not based on existing assumptions or received knowledge about risk factors, which are at best a suggestive framework, the results have so far shown to be far more accurate, especially at predictive, pre-diagnosis discovery.
Overall, the project is intended to help healthcare professionals put together the right screening program for individuals in their care and eliminate the heartbreaking and all-too common outcome of late diagnosis. MIT hopes the technique can also be used to improve detection of other diseases that have similar problems with existing risk models with far too many gaps and lower degrees of accuracy.

Fed Officials Visit Bloomington, IN as Baxter Signs Pledge to America’s Workers

Today, Health and Human Services Secretary Alex Azar and Assistant to the President and Director of the White House Domestic Policy Council Joe Grogan visited Baxter International Inc.’sBloomington, Indiana facility where Baxter signed the Pledge to America’s Workers, committing to nearly 2,000 employee development opportunities over the next five years.
At Baxter, Secretary Azar and Director Grogan participated in a tour of Baxter’s manufacturing, research and development facilities, led by Baxter CEO Jose Almeida. In a roundtable after the tour, Almeida expressed the enthusiastic support of Baxter for President Trump’s executive order on Transforming American Kidney Health and discussed the need for employees at many of Baxter’s U.S. facilities.
At the signing ceremony, Almeida discussed the $500 million in potential investments in new and existing U.S. facilities that make and distribute products for peritoneal dialysis, supporting the Trump Administration kidney health initiative and potentially creating 1,000 U.S. manufacturing jobs.
Secretary Azar spoke about the importance of the President’s Advancing American Kidney Health Initiative, which seeks to reduce the number of Americans developing end-stage renal disease (ESRD) by 25 percent by 2030; have 80 percent of new ESRD patients in 2025 receiving dialysis at home, benefiting from new treatment options, or receiving a transplant; and doubling the number of kidneys available for transplant by 2030.
Director Grogan discussed the roaring economy and the President’s Pledge to America’s Workers, an initiative that calls on employers large and small to create more jobs, strengthen our economy, and restore hopeful futures to countless families.
Bruce Pleskow, a Baxter employee and ESRD survivor, shared his story of how important peritoneal dialysis was to his battle with ESRD.
Almeida then signed the Pledge to America’s Workers to applause from the approximately 70 Baxter employees in attendance. Baxter joins more than 300 companies and organizations who have signed the Pledge contributing to over 12.7 million new education and training opportunities for American students and workers over the next five years.

Biotech week ahead, Aug. 5

Biotech stocks went about in a steady manner this week amid a slew of big pharma and biotech earnings announcements, a handful of FDA approvals and a few clinical trial readouts. Lexicon Pharmaceuticals, Inc. LXRX 8.4% was a huge casualty as the micro-cap stock fell steeply on severing of a licensing pact with Sanofi SA SNY 1.29%.
Here are the key catalysts that can sway biotech stocks in the unfolding week.

Conferences

  • SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference – Aug. 7, in Boston, Massachusetts
  • Canaccord Genuity Growth Conference – Aug. 7-8, in Boston

Clinical Trial Readouts

Leap Therapeutics Inc LPTX 2.23% is scheduled to provide an update on DKN-01 in combination with Merck & Co., Inc. MRK 0.93%‘s Keytruda in ornithine transcarbamylase deficiency.
Pending Mid-2019 Clinical Readouts
Immunic Inc IMUX 1.13% – interim Phase 2 dosing analysis for IMU-838 in ulcerative colitis
Conatus Pharmaceuticals Inc CNAT 7.1% – 48-week liver function data from a Phase 2 study dubbed ENCORE-PH for emricasan in non-alcoholic steatohepatitis cirrhosis
Alkermes Plc ALKS 3.04% – Phase 3 top-line data for diroximel fumarate in relapsing remitting multiple sclerosis
IMMUTEP LTD/S ADR IMMP 2.63% – initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer and head and neck cancer
Aevi Genomic Medicine Inc GNMX 1.62% – Phase 1b data for AEVI-002 in pediatric onset Crohn’s disease
Tricida Inc TCDA 5.31% – 12-month registration stability data from a Phase 3 study of TRC 101 in chronic kidney disease
Curis, Inc. CRIS 2.17% – Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma
Ultragenyx Pharmaceutical Inc RARE 7.89% – Phase 1/2 data from the second cohort that is evaluating its DTX401 in Glycogen storage disease type 1 & Phase 1/2 third cohort data for DTX301 in ornithine transcarbamylase
Allakos Inc ALLK 4.59% – Phase 2 top-line data for AK002 in eosinophilic gastritis
Leap Therapeutics Inc LPTX 2.23%– Phase 1/2 data for DKN-01 + Keytruda in esophagogastric adenocarcinoma
Cidara Therapeutics Inc CDTX 1.48% – Phase 2 data for rezafungin in candidemia
Akcea Therapeutics Inc AKCA 3.84% – Phase 3 data for volanesorsen in familial partial lipodystrophy
Deciphera Pharmaceuticals Inc DCPH 0.49% and Zai Lab Ltd ZLAB 1.72% – Phase 3 data for DCC-2618 from a study dubbed INVICTUS in gastrointestinal stromal tumors
ZEALAND PHARMA/S ADR ZEAL 1.66% – Phase 1b data for dasiglucagon in obesity/diabetes
Aclaris Therapeutics Inc ACRS 8.26% – Phase 2 open label 6-month data for ATI-502 in vitiligo and Phase 2 data for ATI-502 in atopic dermatitis
AnaptysBio Inc ANAB 4.39% – Phase 2 data for ANB019 in generalized pustular psoriasis
Spark Therapeutics Inc ONCE 1.04% – additional Phase 1/2 data for SPK-8011 in hemophilia A

Earnings

Monday, Aug. 5
Tuesday, Aug. 6
  • Gamida Cell Ltd GMDA 1.89% (before the market open)
  • Karyopharm Therapeutics Inc KPTI 5.9% (before the market open)
  • GW Pharmaceuticals PLC- ADR GWPH 1.25% (after the close)
  • HTG Molecular Diagnostics Inc HTGM 2.26% (after the close)
  • Jazz Pharmaceuticals PLC JAZZ 1.3% (after the close)
Wednesday, Aug. 7
  • Jounce Therapeutics Inc JNCE 9.34% (before the market open)
  • PDL BioPharma Inc PDLI 2.11% (after the close)
  • Cara Therapeutics Inc CARA 1.14% (after the close)
  • Sarepta Therapeutics Inc SRPT 1.27% (after the close)
  • Dynavax Technologies Corporation DVAX 1.08% (after the close)
Thursday, Aug. 8
  • Axsome Therapeutics Inc AXSM 0.96% (before the market open)
  • Achieve Life Sciences Inc ACHV 1.65% (before the market open)
  • Adamas Pharmaceuticals Inc ADMS 1.5% (after the close)
  • Nektar Therapeutics NKTR 0.32% (after the close)
  • Puma Biotechnology Inc PBYI 4.56% (after the close)
Friday, Aug. 9
  • Avadel Pharmaceuticals PLC AVDL 2.23% (before the market open)
  • Diplomat Pharmacy Inc DPLO 4.19% (before the market open)
  • PLx Pharma Inc PLXP 0.33% (before the market open)

IPO

BioVie, a biopharma company developing drug therapies for liver diseases, proposes to offer $1.26 million in an IPO, likely to be priced at $11.88. The company intends to list its shares on the Nasdaq under the ticker symbol BIVI.
Israeli medical device maker InMode filed for offering 5 million shares in an IPO, at an estimated price range of $14-$16. The shares are to be listed on the Nasdaq under the ticker symbol INMD.

Buy prescription drugs, other crazy things hackers do with your data

The type of personal information compromised in thefts like Capital One’sCOF, -1.16%   data hack could hold the “keys to the kingdom” for a bad actor, experts say — and she or he can do far more than open a credit card in your name.
The company revealed Monday night that it had learned of a hack impacting about 100 million U.S. customers and 6 million people in Canada. Authorities charged 33-year-old software engineer Paige Thompson, a former Amazon Web Services AMZN, -1.73%   employee, with one count of computer fraud and abuse, an offense that carries up to five years in prison.
Though Capital One stressed in a statement that “no credit-card account numbers or log-in credentials were compromised and over 99% of Social Security numbers were not compromised,” it conceded that some 140,000 Social Security numbers and 80,000 linked bank-account numbers had indeed been compromised. Other compromised information included names, dates of birth, self-reported income, addresses, zip codes, email addresses and phone numbers, the company said.
‘The Social Security number basically is a password.’
“Based on our analysis to date, we believe it is unlikely that the information was used for fraud or disseminated by this individual,” Capital One said. “However, we will continue to investigate.” The company said it would notify impacted customers “through a variety of channels” and provide them with free identity protection and credit monitoring.
The Social Security numbers from credit-card applications had been “tokenized or encrypted,” according to a Justice Department complaint, while information like names, dates of birth, addresses and credit-history information had not. But security experts warn that in general, Social Security numbers and other personal details can be exploited for purposes well beyond taking out a line of credit — including medical, employment and criminal identity theft.
“That [Social Security number] is connected to so many credit-driven and governmental services, and what most people don’t realize is that the Social Security number basically is a password,” Robert Siciliano, a security and privacy expert at the online security resource Safr.Me, told MarketWatch. “It shouldn’t be that easy, but that’s what our credit system, banks, lenders, retailers and our government has designed — and they didn’t really think that one through.”
An enterprising identity thief might pose as you using your Social Security number to get a job.
Plus, “combined with other major breaches, like Equifax EFX, -0.09%  , the SSNs can still be used to steal identities when correlated with other personally identifying data in those other public data dumps,” said Katie Moussouris, the founder and CEO of Luta Security.
In the wake of a large data breach like this one, consumers should check if their accounts have been affected, sign up for additional fraud protection and understand the difference between a credit freeze and a credit lock. But they should also consider several other ways in which a bad actor could exploit their personal data.
Here are five more worst-case scenarios to watch out for — and how best to protect yourself:
An imposter gets a job under your name. An enterprising identity thief might pose as you using your Social Security number (along with an easily obtainable fake ID) to get a job, Siciliano said. The imposter’s wages could then be reported in your name, sticking you with an Internal Revenue Service tax bill you shouldn’t owe.
While there isn’t much you can do to prevent this from happening, identity-theft and privacy expert Carrie Kerskie said, you can freeze your Social Security number in E-Verify, the government tool used by some employers to verify employment eligibility.
An imposter using your name and personal identity to access health care can be costly to resolve and potentially dangerous to your health.
E-Verify lets users “Self Lock” their Social Security number and unlock it whenever a new employer needs to vet them. “If your locked SSN is entered in E-Verify to confirm employment authorization, it will result in an E-Verify mismatch, called a tentative non-confirmation,” E-Verify’s site says. “By using Self Lock, you can block someone from committing this fraud if they gain employment with an E-Verify employer.” But “this isn’t 100%,” Kerskie said, as not every employer uses this system.
Someone claims your Social Security benefits or files taxes under your name.Though this reportedly isn’t a foolproof approach, you should create a MySSA account with the Social Security Administration, Kerskie said. “If you don’t set it up, you leave it wide open for a bad guy to do it on your behalf,” she said. “So by setting it up, you’re marking your territory.” Anyone over age 18 with the required information can create an online account.
As for fraud related to tax returns, you may be eligible to use an IRS Identity Protection PIN (IP PIN) — which bars another person from filing tax returns using your Social Security Number — on your federal income tax returns. Eligible parties will have received a CP01A notice from the IRS; received a letter from the IRS inviting them to get an IP PIN; or filed their federal return last year as a California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Nevada, Rhode Island or Washington, D.C. resident.
In some cases, like if the IRS rejects your tax return because someone has already filed a return using your Social Security number, you may be able to fill out an identity-theft affidavit (Form 14039).
Someone uses your identity to obtain medical services or prescription drugs. An imposter’s using your name and personal identity to access health care can be costly to resolve and potentially dangerous to your health. After all, Kerskie said, this person’s test results and symptoms could wind up on your medical record. “When you go to the doctor and they’re trying to make a diagnosis, are they looking at only your symptoms and your test results, or are they commingled with your imposter’s?” Kerskie said. “There have been situations where it’s led to misdiagnosis.”
A bad actor gaining access to your calls and text messages also spells bad news for two-factor authentication that uses SMS codes.
Your best defense against medical identity theft is monitoring, Kerskie said. Scrutinize any explanation of benefits you receive from your insurance company, noting dates, names of providers and summaries of services rendered, she said, calling your insurance company to report any discrepancies. Ask your health-care provider for a copy of your medical file, Kerskie added, and speak up if a provider mentions any medications or tests you haven’t received. “You can’t err on the side of caution,” she said. “You have to ask questions.”
A thief hijacks your cell phone — and is now receiving all of your calls and texts.They can achieve this by transferring your phone account to another carrier, Kerskie said, or by using your personal information to call your carrier and switch your SIM card to a new device. And while many mobile carriers allow customers to create a PIN or passcode as an extra layer of security beyond their name, address, date of birth and Social Security number, Kerskie says many people lean on lazy, easy-to-guess passwords using their birthday or the last four digits of their Social.
A bad actor gaining access to your calls and text messages also spells bad news for two-factor authentication that uses SMS codes. “The bad guys know this — so once they steal your number, they will go to major financial institutions and they will initiate a password reset for your account,” Kerskie said.
As data breaches are only likely to grow more common, you should protect yourself using multi-factor authentication through an app like Google Authenticator GOOG, -1.24% GOOGL, -1.28%  or Microsoft AuthenticatorMSFT, -0.84%, Moussouris said. For additional protection, you could go with a hardware-based security token, she added.
Someone steals your identity and gets charged with a crime. This could negatively impact your own job prospects if you have a criminal record you’re unaware of, Kerskie said, or even affect your car-insurance rates if someone is racking up traffic violations in your name.
Try requesting your criminal background check from your county, your state or some other database, she suggested, or request an Identity History Summaryfrom the FBI. Google your name every now and then to see what turns up, she added. “If there’s anything that seems off,” she said, “you need to take some extra time and some extra steps to look into it.”

Genetic Testing: A Rising Star in Preventive Screening

Although we tend to think of population-wide genetic testing as a relative newcomer, it made its debut more than half a century ago when we began to test all newborns for phenylketonuria (PKU), an inborn metabolic error that, left untreated, resulted in mental retardation.
In the 1970s, population-wide testing was initiated for two other serious, life-threatening conditions that are passed to children by their parent carriers – sickle cell disease in the African-American population and Tay-Sachs disease in the Jewish population. Serum marker screening tests were introduced as well (e.g., Down syndrome, cystic fibrosis) and offered to all pregnant women.
It’s hard to believe that, until the early 2000s, genetic testing was only available when clinically indicated and ordered by a physician, with board-certified providers interpreting and delivering the results; essentially, all responsibility for the security and quality of genetic information resided within the healthcare system.
I can still recall hearing about one early direct-to-consumer (DTC) genetic testing campaign – a “Spit Party” that launched 23and Me – and thinking that it wouldn’t take long for these tests to become part of a routine patient workup. Today, DTC genetic testing is evolving at breakneck speed as a result of market competition, mounting consumer interest, and ongoing research into the effect of genetics on personal health; employee genetic testing is becoming a bona fide trend.
This being the case, it came as no surprise when Jefferson (my employer, and one of the Philadelphia region’s largest health employers) rolled out a free genetic testing benefit … and more than 10% of its 30,000 workers accepted the offer in the first couple of months.
Produced by a California-based firm (Color Genomics), the panel of genetic tests offered by Jefferson includes cancer risk (30 genes), heart disease risk (30 genes), and medication metabolism (14 genes). To avoid confusion or undue anxiety about test results that show a high risk for a potentially life-threatening condition, every test includes free telephone sessions with genetic counselors. And, as part of the benefit, Jefferson also will pay for additional screening tests (e.g., mammograms, colonoscopies) or preventive medications for employees who discover they have potentially dangerous genetic mutations.
Employees were quick to recognize the benefits for them, but what are the benefits to an employer like Jefferson? First, offering the benefit conveys a message that the employer cares about the employees’ health and long-term wellbeing; and this, in turn, may have a positive effect on loyalty to the institution. Second, chances are good that it may help bend the long-term cost curve by preventing or delaying the onset of expensive and disabling cancers, strokes, and heart attacks.
As the genetic testing trend gathers momentum, I foresee an even greater benefit for the health of the nation’s entire population.
In my view, population-wide genetic testing lends support to both the Triple Aim (i.e., improving the health of the population, reducing per capita cost, and enhancing the experience of care) and the National Institute of Health’s All of Us Research Program goals for precision medicine.